Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 20/20 | 0.60 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gw786460X SCHEMBL29398528 | 1.00 | TGFBR1 (0.60) | TGFBR1MAPK14MTOR | |
| Gw786460X SCHEMBL29889251 | 0.99 | TGFBR1 (0.59) | TGFBR1MAPK14MTOR | |
| Gw786460X SCHEMBL26962436 | 0.99 | TGFBR1 (0.59) | TGFBR1MAPK14MTOR | |
| SCHEMBL20822412 | 0.86 | TGFBR1 (0.44) | TGFBR1MAPK14 | |
| SCHEMBL373397 | 0.84 | TGFBR1 (0.56) | TGFBR1MAPK14MTOR | |
| SCHEMBL25822564 | 0.83 | TGFBR1 (0.44) | TGFBR1MAPK14MTOR | |
| SCHEMBL27842262 | 0.82 | TGFBR1 (0.41) | TGFBR1MAPK14 | |
| SCHEMBL25085206 | 0.82 | TGFBR1 (0.47) | TGFBR1MAPK14MTOR | |
| SCHEMBL30156338 | 0.82 | TGFBR1 (0.47) | TGFBR1MAPK14MTOR | |
| Hydrochloric Acid SCHEMBL31572311 | 0.82 | AR (0.50) | TGFBR1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260097083-A1 | METHOD FOR PRODUCING PANCREATIC ENDODERM CELLS | KYOTO UNIVERSITY (JP) | 2026-04-09 | — | — | US | claimed |
| EP-4692329-A1 | COMPOSITION FOR INDUCING DIRECT DIFFERENTIATION OF STEM CELLS INTO CORNEAL ENDOTHELIAL CELLS AND METHOD FOR INDUCING DIRECT DIFFERENTIATION USING SAME | The Asan Foundation (KR) | 2026-02-11 | — | — | EP | claimed |
| EP-3784232-B1 | IMPROVED METHODS FOR INDUCING TISSUE REGENERATION AND SENOLYSIS IN MAMMALIAN CELLS | AGEX THERAPEUTICS INC (US) | 2026-02-11 | — | — | EP | claimed |
| US-12427147-B2 | Retinal ganglion cell death inhibitor | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2025-09-30 | — | — | US | claimed |
| EP-3047017-B1 | METHODS OF MAMMALIAN RETINAL STEM CELL PRODUCTION AND APPLICATIONS | UNIV CALIFORNIA (US) | 2025-09-10 | — | — | EP | claimed |
| EP-4596675-A1 | METHOD FOR PRODUCING PANCREATIC ENDODERM CELLS | Kyoto University (JP) | 2025-08-06 | — | — | EP | claimed |
| US-12371664-B2 | Medium for direct differentiation of pluripotent stem cell-derived mesenchymal stem cell, method for preparing mesenchymal stem cell by using same, and mesenchymal stem cell prepared thereby | CHA BIOTECH CO., LTD. (KR) | 2025-07-29 | — | — | US | claimed |
| US-20250188420-A1 | MATURING AGENT HAVING BOTH OF ALK5 INHIBITORY ACTIVITY AND CDK8/19 INHIBITORY ACTIVITY | Orizuru Therapeutics, Inc. (JP) | 2025-06-12 | — | — | US | claimed |
| EP-4516894-A1 | MATURING AGENT HAVING BOTH OF ALK5 INHIBITORY ACTIVITY AND CDK8/19 INHIBITORY ACTIVITY | Orizuru Therapeutics, Inc. (JP) | 2025-03-05 | — | — | EP | claimed |
| US-RE50313-E1 | Musculoskeletal stem cell and medium for inducing differentiation of musculoskeletal stem cell | CELLATOZ THERAPEUTICS, INC. (KR) | 2025-02-25 | — | — | US | claimed |
| US-20130236436-A1 | EXPANDABLE CELL SOURCE OF NEURONAL STEM CELL POPULATIONS AND METHODS FOR OBTAINING AND USNIG THEM | ZHANG KANG (US) | 2013-09-12 | — | — | US | claimed |
| US-20130071931-A1 | PROCESS FOR HEPATIC DIFFERENTIATION FROM INDUCED HEPATIC STEM CELLS, AND INDUCED HEPATIC PROGENITOR CELLS DIFFERENTIATED THEREBY | NATIONAL CANCER CENTER (JP) | 2013-03-21 | — | — | US | claimed |
| US-20130022986-A1 | METHOD FOR MANUFACTURING PANCREATIC-HORMONE-PRODUCING CELLS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-24 | — | — | US | claimed |
| US-8298825-B1 | TGF-beta receptor inhibitors to enhance direct reprogramming | THE GENERAL HOSPITAL CORPORATION (US) | 2012-10-30 | — | — | US | claimed |
| EP-2505639-A1 | METHOD FOR MANUFACTURING PANCREATIC-HORMONE-PRODUCING CELLS | Takeda Pharmaceutical Company Limited (JP) | 2012-10-03 | — | — | EP | claimed |
| EP-2229434-B1 | DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS | LIFESCAN INC (US) | 2011-09-07 | — | — | EP | claimed |
| EP-2229434-A2 | DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS | Lifescan, Inc. (US) | 2010-09-22 | — | — | EP | claimed |
| US-20100167300-A1 | MICROENVIRONMENT NICHE ASSAY FOR CiPS SCREENING | ESMAELI-AZAD, BABAK | 2010-07-01 | — | — | US | claimed |
| US-20090170198-A1 | Differentiation of human embryonic stem cells | JANSSEN BIOTECH, INC. | 2009-07-02 | — | — | US | claimed |
| WO-2009070592-A2 | DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS | LIFESCAN, INC. (US) | 2009-06-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097083-A1 | METHOD FOR PRODUCING PANCREATIC ENDODERM CELLS | PNLIP, GIPR, CEL | TGFBR1 1634/4885MAPK14 580/4885MTOR 769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.